Zoetis Inc. (ZTS)
Zoetis (ZTS) Outpaces Stock Market Gains: What You Should Know
In the most recent trading session, Zoetis (ZTS) closed at $74.81, indicating a +2.37% shift from the previous trading day.
Zoetis (ZTS) Stock Sinks As Market Gains: Here's Why
Zoetis (ZTS) reached $69.1 at the closing of the latest trading day, reflecting a -1.05% change compared to its last close.
Zoetis: Priced For The Worst, Worth Buying
Zoetis Inc. (ZTS) has fallen 71% from its 2021 peak, now trading at 2017 levels, as pricing power eroded and pet medicine volumes declined. Despite near-term headwinds, Zoetis maintains industry-leading margins and is positioned to weather price wars better than rivals due to its product mix and scale. Patent expiries for Apoquel and Simparica in 2030/2032 are key risks, but a robust pipeline of 12 candidates could offset revenue losses if half succeed.
Zoetis (ZTS) Stock Drops Despite Market Gains: Important Facts to Note
Zoetis (ZTS) closed at $71.4 in the latest trading session, marking a -2.22% move from the prior day.
Zoetis: The Worst May Be Priced In
Zoetis faces ongoing headwinds but is now considered a cautious 'Buy' as valuation reflects low-to-mid single-digit growth potential. Q2 results disappointed, with flat revenues and declining U.S. sales, but international and livestock segments showed resilience and growth. Management revised 2026 guidance downward, but ZTS's low valuation multiples and aggressive share buybacks support its fair value case.
Zoetis Stands by Guidance as Pet-Care Weakness and Competition Pressure Sales
Zoetis NYSE: ZTS executives said the company remains confident in its previously issued guidance despite pressure in the U.S. companion-animal market, citing a weaker pet-care environment and intensified competition in dermatology and parasiticides.
Zoetis: An Undervalued Compounder Hiding In Plain Sight
Zoetis is rated a buy, as I see current headwinds as temporary and the stock undervalued based on my DCF valuation. ZTS faces near-term pressure from weaker U.S. companion animal demand, increased competition, and margin compression due to promotions and rebates. Long-term growth is supported by structural pet humanization trends, international expansion, a robust R&D pipeline, and a growing diagnostics segment.
Zoetis: A Solid Long-Term Buy After Harsh Drawdown
Zoetis is navigating the worst drawdown in its stock history, driven by weakening U.S. vet clinic traffic and heightened competition across key companion animal franchises. Despite aggressive competitor promotions, Zoetis protects industry-leading profitability (35%–37% EBIT margins) using targeted gross-to-net rebates rather than base list-price cuts. Trading at a historic low 12x P/E and a 7%+ FCF yield, Zoetis offers a strong margin of safety compared to its Base Case DCF fair value of $100.06.
Zoetis: Another Bad Quarter, Some Value Trap Risk But Shares Still Cheap
Zoetis' Q2 earnings results were mixed, and the company cut its forward guidance. This has reduced the stock's margin of safety, but on balance, the risk/reward profile still favors the bulls. Zoetis has other segments performing well which partially offset the weakness in U.S. pet-related sales.
Zoetis: The Growth Story Has Broken, But The Valuation Finally Makes Sense
Zoetis (ZTS) now trades at just 12x forward earnings, with a nearly 3% dividend yield and gross margins above 70%, after a severe multiyear drawdown. Competition, weaker U.S. companion animal sales, and reduced guidance have pressured ZTS, but its core profitability and market dominance remain intact. Management is aggressively repurchasing shares, capital returns are strong, and the balance sheet remains healthy despite $9B in long-term debt.
Zoetis gets US FDA emergency use nod for treatment for screwworm in dogs
The U.S. Food and Drug Administration on Thursday issued an emergency use authorization for Zoetis' flea and tick drug to treat New World screwworm (NWS) infestations in dogs and puppies.
Zoetis Q2 Earnings Call Highlights
Zoetis NYSE: ZTS reported second-quarter revenue of $2.5 billion, flat on a reported basis and down 1% organically, as pressure in U.S. companion-animal categories offset growth in livestock, diagnostics and international markets. Adjusted net income was $781 million, down 2% organically, while adjusted diluted earnings per share rose 4% to $1.87, benefiting from a lower share count following share repurchases.
